Skip to main content
logo
Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
504.22
-2.52 (-0.50%)
Oct 2, 2026, 1:19 PM EDT - Market open

Vertex Pharmaceuticals Revenue by Segment

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Trikafta and Kaftrio
10.39B10.29B10.19B9.81B9.50B9.29B8.94B8.63BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Trikafta and Kaftrio Growth
9.44%10.80%13.95%13.59%13.46%15.77%16.36%17.33%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Kalydeco
---112.40M225.20M350.50M475.50M499.20MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Kalydeco Growth
----77.48%-57.17%-35.00%-14.05%-12.31%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Orkambi
---44.20M107.20M203.50M326.00M392.60MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Orkambi Growth
----88.74%-77.47%-59.39%-36.17%-28.27%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Symdeko and Semkevi
---27.80M61.20M92.40M123.00M129.50MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Symdeko and Semkevi Growth
----78.53%-54.43%-36.63%-31.67%-42.72%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Revenue By Geography

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
United States
7.90B7.67B7.55B7.29B7.03B6.82B6.68B6.42BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
United States Growth
12.35%12.50%12.92%13.58%12.27%10.75%10.67%8.37%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Europe
3.65B3.58B3.46B3.41B3.42B3.31B3.45B3.36BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Europe Growth
6.83%8.17%0.19%1.47%4.31%1.34%11.09%9.68%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Other
1.07B973.30M992.40M991.70M939.20M958.10M881.30M846.30MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Other Growth
13.66%1.59%12.61%17.18%17.64%26.18%22.44%26.86%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Revenue By Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Trikafta and Kaftrio
10.08B10.13B10.31B10.46B10.39B10.29B10.19B9.81BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Trikafta and Kaftrio Growth
-3.02%-1.53%1.18%6.67%9.44%10.80%13.95%13.59%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Kalydeco
-------112.40MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Kalydeco Growth
--------77.48%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Orkambi
-------44.20MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Orkambi Growth
--------88.74%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Symdeko and Semkevi
-------27.80MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Symdeko and Semkevi Growth
--------78.53%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Revenue by Geography

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
United States
7.03B6.82B6.68B6.42B6.26B6.16B6.04B5.93BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
United States Growth
12.27%10.75%10.67%8.37%7.47%7.35%5.98%5.21%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Europe
3.42B3.31B3.45B3.36B3.28B3.27B3.11B3.06BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Europe Growth
4.31%1.34%11.09%9.68%8.30%13.50%14.91%17.34%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Other
939.20M958.10M881.30M846.30M798.40M759.30M719.80M667.10MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Other Growth
17.64%26.18%22.44%26.86%22.36%28.11%36.87%45.31%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Operating Expense Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Research and Development
3.91B3.89B3.91B3.93B3.83B3.82B3.63B3.46BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Research and Development Growth
1.93%1.85%7.69%13.84%13.05%19.05%14.78%13.98%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Selling, General, and Administrative
2.01B1.85B1.75B1.64B1.57B1.52B1.46B1.46BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Selling, General, and Administrative Growth
27.87%21.90%19.72%12.91%16.52%22.60%28.83%40.67%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Acquired In-Process Research and Development
132.90M113.70M133.00M164.00M124.50M4.57B4.63B4.56BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Acquired In-Process Research and Development Growth
6.75%-97.51%-97.13%-96.40%-97.29%1,680.14%778.09%757.06%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Change in Value of Contingent Consideration
-400.00K100.00K2.10M-2.20M1.80M-500.00K-49.60MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Change in Value of Contingent Consideration Growth
--94.44%------UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade